BCMA-directed CAR-T cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia

This first clinical evaluation of BCMA CAR-T cell therapy in four patients with refractory primary ITP demonstrated manageable safety, rapid and sustained platelet recovery, and durable drug-free complete remission lasting up to 15 months, supporting further evaluation in larger studies.